PAHC Stock Analysis: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$33.26
1.16 (3.61%)
▲
5d:
+4.49%
30d:
+16.62%
90d:
-39.26%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 26, 2026
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PAHC shows positive signals but monitor for confirmation. Market pricing in 10.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: PAHC shows positive signals but monitor for confirmation. Market pricing in 10.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.41
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$39.99
16.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $33.26, which is considered extended relative to its 30-day fair value range of $30.62 to $32.57. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (14.1). Remarkably, the market is currently pricing in an annual earnings decline of 10.9% over the next few years. This pessimistic expectation contrasts with the company's recent 15.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is approaching resistance at $33.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: PAHC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $45.60 (+37.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is approaching resistance at $33.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: PAHC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $45.60 (+37.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$30.62 -
$32.57
Company Quality Score
54/100
(HOLD)
Options IV Signal
13th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
73.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 13th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 37.1% below Wall St target ($45.60)
Trading Range Analysis
30-Day Trading Range
$30.62 -
$32.57
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.73
(8.2%)
Support & Resistance Levels
Support Level
$30.46
Resistance Level
$33.35
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.95
Wall Street Target
$45.60
(+37.1%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
15.7%
Profit Margin
6.3%
Valuation Discount vs History
-10.9% cheaper
PE vs Historical
10.0 vs 14.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.9%
(market-implied from PE analysis)
1-Year Target
$29.93
(-10%)
2-Year Target
$26.94
(-19%)
3-Year Target
$24.25
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→14)
$34.37
(+3%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.9%)
$93.93
(+182%)
Base:
(SPY PE: 9.9, Growth: 8.9%)
$42.90
(+29%)
Bear:
(PE: 8.5, Growth: 8.9%)
$36.46
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.78 | Current EPS (TTM): $2.33
Bull Case
$50.68
(+52%)
Analyst growth 43.5%, PE expands to 15.2
Base Case
$46.07
(+39%)
Market implied 43.5%, PE stable at 13.8
Bear Case
$21.83
(-34%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.9 to 14.1
Stabilization Target:
$47.15
(+41.8%)
PE Expansion Potential:
+41.8%
Share & Embed Analysis
Last updated: July 05, 2026 3:25 AM ET
Data refreshes hourly during market hours. Next update: 4:25 AM
Data refreshes hourly during market hours. Next update: 4:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Jack Bendheim
SELL
7040 shares
2026-04-22
Jack Bendheim
SELL
7040 shares
2026-04-16
Jack Bendheim
SELL
7040 shares
2026-04-14
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
